NEW YORK, May 5 (GenomeWeb News) - Invitrogen yesterday announced an agreement with the National Human Genome Research Institute and the National Cancer Institute to institute open access to the company's Gateway and SuperScript technologies for use with the Mammalian Gene Collection program.
Gateway is a method for cloning DNA sequences for functional study. Additionally, some Gateway vectors allow for the synthesis of protein products. Under Invitrogen's licensing policies, academic and government researchers can create and distribute Gateway clones and expression clones to any entity without royalties or licensing fees.
The Mammalian Gene Collection program is an NIH-funded effort to generated sequenced full-length cDNAs.